<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125939</url>
  </required_header>
  <id_info>
    <org_study_id>EGH-2022-1</org_study_id>
    <nct_id>NCT05125939</nct_id>
  </id_info>
  <brief_title>Whether Overall Adenoma Detection Rate Can Replace Screening Adenoma Detection Rate ? Multicenter Study</brief_title>
  <official_title>Improving Colonoscopy Adenoma Detection Metrics by Extending the Screening-only Measurement to All Indications: a Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Evergreen General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>E-Da Dachang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sepulveda Ambulatory Care Center, Veterans Affairs Greater Los Angeles Healthcare System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Evergreen General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective equivalence colonoscopy study evaluating whether overall adenoma&#xD;
      detection rate (ADR) is a reliable alternate for screening ADR. Overall indication includes&#xD;
      screening, surveillance, and diagnostic indications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter study conducted by 18 colonoscopists from 5 hospitals in Taiwan,&#xD;
      including Evergreen general hospital, E-da hospital, E-da Dachang hospital, Linkou Chang Gung&#xD;
      memorial hospital, and Keelung memorial hospital. Felix W. Leung has been involved in the&#xD;
      study design, and will participate in data analyses and report preparation, but not in&#xD;
      patient enrollment. Consecutive patients aged ≥50 years undergoing colonoscopy are eligible&#xD;
      for enrollment. Positive fecal immunochemical test (FIT+) is considered as an independent&#xD;
      indication category and the colonoscopy indications are categorized into 4 groups: screening,&#xD;
      surveillance, diagnostic, and FIT+. Overall indication will be subdivided into overall&#xD;
      excluding FIT (overall-non-FIT) group and overall including FIT (overall-FIT) group. In this&#xD;
      study, we plan to (1) compare individual ADR across 4 colonoscopy indication categories&#xD;
      (screening, surveillance, diagnostic, FIT+); (2) explore correlations between screening ADR&#xD;
      and overall-non-FIT and overall-FIT ADRs, respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adenoma detection rate</measure>
    <time_frame>7 days</time_frame>
    <description>The proportion of individuals undergoing a complete colonoscopy who have one or more adenomas detected</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">2700</enrollment>
  <condition>Adenoma Detection Rate</condition>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Screening indication</arm_group_label>
    <description>Screening indication includes asymptomatic patients aged ≥50 years with no prior colonoscopy and at average risk of CRC. Screening indication also includes asymptomatic patients with negative prior colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surveillance indication</arm_group_label>
    <description>Surveillance indication includes patients with prior colon neoplasms, including conventional adenomas and clinically significant serrated polyps.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diagnostic indication</arm_group_label>
    <description>Diagnostic indication includes patients who report symptoms (e.g., abdominal pain, a change in bowel habits, or rectal bleeding) before their first screening examination and undergo evaluation of an abnormality on other image study, unexplained anemia and/or unexplained weight loss.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive fecal immunochemical test</arm_group_label>
    <description>FIT+ indication includes patients who undergo colonoscopy for positive FIT results in screen-eligible individuals. FIT+ indication also applies to those with a positive FIT result and a recent colonoscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Comparison of ADR</intervention_name>
    <description>We will compare ADRs using traditional screening-restricted definition and combined screening, surveillance, and diagnostic indication (i.e., overall-non-FIT indication). The impact of addition of FIT+ indication into the overall indication (i.e., overall-FIT indication) on ADR will also be evaluated.</description>
    <arm_group_label>Diagnostic indication</arm_group_label>
    <arm_group_label>Positive fecal immunochemical test</arm_group_label>
    <arm_group_label>Screening indication</arm_group_label>
    <arm_group_label>Surveillance indication</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients aged ≥50 years undergoing screening, surveillance, diagnostic, and FIT+&#xD;
        colonoscopy are eligible for enrollment in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  consecutive patients aged ≥50 years undergoing colonoscopy are eligible for&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  high risk family history of colorectal cancer (CRC) e.g., familial adenomatous&#xD;
             polyposis, hereditary non-polyposis CRC syndrome, multiple first degree relatives with&#xD;
             CRC, or a single first degree relative with CRC at &lt;60 years&#xD;
&#xD;
          -  serrated polyposis syndrome&#xD;
&#xD;
          -  inflammatory bowel disease&#xD;
&#xD;
          -  colonoscopy to remove a large neoplastic polyps&#xD;
&#xD;
          -  obstructive lesions of the colon&#xD;
&#xD;
          -  gastrointestinal bleeding&#xD;
&#xD;
          -  current participation in other studies&#xD;
&#xD;
          -  hospitalized patients&#xD;
&#xD;
          -  mental retardation&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  refusal to provide a written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Chi-Liang Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Evergreen General Hospital, Taoyuan, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chi-Liang Cheng</last_name>
    <phone>0919768058</phone>
    <email>chiliang.cheng@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>E-Da Dachang Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80784</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Jen-Hao Yeh, MD</last_name>
      <email>b9202078@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Wen-Lun Wang, MD</last_name>
      <email>warrengodr@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Shuo-Wei Chen, MD</last_name>
      <email>shuowei.chen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evergreen General Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>320</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chen-Ming Hsu, MD</last_name>
      <email>hsu3060e@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Kahi CJ, Vemulapalli KC, Johnson CS, Rex DK. Improving measurement of the adenoma detection rate and adenoma per colonoscopy quality metric: the Indiana University experience. Gastrointest Endosc. 2014 Mar;79(3):448-54. doi: 10.1016/j.gie.2013.10.013. Epub 2013 Nov 15.</citation>
    <PMID>24246797</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaltenbach T, Gawron A, Meyer CS, Gupta S, Shergill A, Dominitz JA, Soetikno RM, Nguyen-Vu T, A Whooley M, Kahi CJ. Adenoma Detection Rate (ADR) Irrespective of Indication Is Comparable to Screening ADR: Implications for Quality Monitoring. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1883-1889.e1. doi: 10.1016/j.cgh.2021.02.028. Epub 2021 Feb 19.</citation>
    <PMID>33618027</PMID>
  </results_reference>
  <results_reference>
    <citation>Rex DK, Ponugoti PL. Calculating the adenoma detection rate in screening colonoscopies only: Is it necessary? Can it be gamed? Endoscopy. 2017 Nov;49(11):1069-1074. doi: 10.1055/s-0043-113445. Epub 2017 Jul 28.</citation>
    <PMID>28753699</PMID>
  </results_reference>
  <results_reference>
    <citation>Ladabaum U, Shepard J, Mannalithara A. Adenoma and Serrated Lesion Detection by Colonoscopy Indication: The ADR-ESS (ADR Extended to all Screening/Surveillance) Score. Clin Gastroenterol Hepatol. 2021 Sep;19(9):1873-1882. doi: 10.1016/j.cgh.2021.04.027. Epub 2021 Apr 22.</citation>
    <PMID>33895358</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colonoscopy</keyword>
  <keyword>Adenoma detection rate</keyword>
  <keyword>Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

